388 related articles for article (PubMed ID: 9416842)
1. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.
Gloushankova N; Ossovskaya V; Vasiliev J; Chumakov P; Kopnin B
Oncogene; 1997 Dec; 15(24):2985-9. PubMed ID: 9416842
[TBL] [Abstract][Full Text] [Related]
2. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.
Kopnin BP; Stromskaya TP; Kondratov RV; Ossovskaya VS; Pugacheva EN; Rybalkina EY; Khokhlova OA; Chumakov PM
Oncol Res; 1995; 7(6):299-306. PubMed ID: 8527864
[TBL] [Abstract][Full Text] [Related]
3. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
[TBL] [Abstract][Full Text] [Related]
4. [Opposite effect of p53 on nucleotide metabolizing enzyme activity in Rat1 cells and their sublines, transformed by N-RAS or v-mos oncogenes].
Khramtsova SN; Osovskaia VS; Semeniak OIu; Potapova GI; Chumakov PM; Kopnin BP
Biokhimiia; 1995 Nov; 60(11):1881-8. PubMed ID: 8590759
[TBL] [Abstract][Full Text] [Related]
5. P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints.
Agapova LS; Ivanov AV; Sablina AA; Kopnin PB; Sokova OI; Chumakov PM; Kopnin BP
Oncogene; 1999 May; 18(20):3135-42. PubMed ID: 10340385
[TBL] [Abstract][Full Text] [Related]
6. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
7. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras.
Gapuzan ME; Schmah O; Pollock AD; Hoffmann A; Gilmore TD
Oncogene; 2005 Sep; 24(43):6574-83. PubMed ID: 16027734
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells.
Kremenetskaya OS; Logacheva NP; Baryshnikov AY; Chumakov PM; Kopnin BP
Oncol Res; 1997; 9(4):155-66. PubMed ID: 9268986
[TBL] [Abstract][Full Text] [Related]
9. [Morphology, cell-cell interactions, and migratory activity of IAR-2 epithelial cells transformed with the RAS oncogene: contribution of cell adhesion protein E-cadherin].
Zhitniak IIu; Glushankova NA
Ontogenez; 2011; 42(6):453-64. PubMed ID: 22288108
[TBL] [Abstract][Full Text] [Related]
10. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization.
Alexandrova A; Ivanov A; Chumakov P; Kopnin B; Vasiliev J
Oncogene; 2000 Nov; 19(50):5826-30. PubMed ID: 11126371
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation.
Izawa I; Amano M; Chihara K; Yamamoto T; Kaibuchi K
Oncogene; 1998 Dec; 17(22):2863-71. PubMed ID: 9879992
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localization is essential for the activity of p53 protein.
Shaulsky G; Goldfinger N; Tosky MS; Levine AJ; Rotter V
Oncogene; 1991 Nov; 6(11):2055-65. PubMed ID: 1719467
[TBL] [Abstract][Full Text] [Related]
13. Responses of epithelial and fibroblast-like cells to discontinuous configuration of the culture substrate.
Rovensky YuA ; Domnina LV; Ivanova OYu ; Vasiliev JM
Membr Cell Biol; 2001 Jul; 14(5):617-27. PubMed ID: 11699865
[TBL] [Abstract][Full Text] [Related]
14. [The protective role of p53 in Ras-induced transformation of REF52 cells].
Kopnin PB; Ivanov AV; Il'inskaia GV; Sablina AA; Kopnin BP; Chumakov PM
Mol Biol (Mosk); 2003; 37(3):458-71. PubMed ID: 12815953
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B.
Yam JW; Chan KW; Hsiao WL
Oncogene; 2001 Jan; 20(1):58-68. PubMed ID: 11244504
[TBL] [Abstract][Full Text] [Related]
16. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis.
Jo H; Zhang R; Zhang H; McKinsey TA; Shao J; Beauchamp RD; Ballard DW; Liang P
Oncogene; 2000 Feb; 19(7):841-9. PubMed ID: 10702792
[TBL] [Abstract][Full Text] [Related]
17. Cylindrical substratum induces different patterns of actin microfilament bundles in nontransformed and in ras-transformed epitheliocytes.
Levina EM; Domnina LV; Rovensky YA; Vasiliev JM
Exp Cell Res; 1996 Nov; 229(1):159-65. PubMed ID: 8940260
[TBL] [Abstract][Full Text] [Related]
18. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
19. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
20. Transformation by RAS oncogene decreases the width of substrate-spread fibroblasts but not their length.
Kharitonova MA; Kopnin PB; Vasiliev JM
Cell Biol Int; 2007 Mar; 31(3):220-3. PubMed ID: 17142064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
